GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (STU:4OR1) » Definitions » Shiller PE Ratio

Organovo Holdings (STU:4OR1) Shiller PE Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Organovo Holdings Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Organovo Holdings Shiller PE Ratio Historical Data

The historical data trend for Organovo Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Shiller PE Ratio Chart

Organovo Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Organovo Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Organovo Holdings's Shiller PE Ratio

For the Biotechnology subindustry, Organovo Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organovo Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's Shiller PE Ratio falls into.



Organovo Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Organovo Holdings's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Organovo Holdings's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.267/131.7762*131.7762
=-0.267

Current CPI (Mar. 2024) = 131.7762.

Organovo Holdings Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.178 100.560 -1.544
201409 -1.707 100.428 -2.240
201412 -1.460 99.070 -1.942
201503 -1.848 99.621 -2.444
201506 -1.782 100.684 -2.332
201509 -2.138 100.392 -2.806
201512 -2.020 99.792 -2.667
201603 -1.627 100.470 -2.134
201606 -1.602 101.688 -2.076
201609 -1.782 101.861 -2.305
201612 -1.706 101.863 -2.207
201703 -1.870 102.862 -2.396
201706 -1.780 103.349 -2.270
201709 -1.510 104.136 -1.911
201712 -1.183 104.011 -1.499
201803 -1.135 105.290 -1.421
201806 -1.198 106.317 -1.485
201809 -0.857 106.507 -1.060
201812 -1.055 105.998 -1.312
201903 -1.062 107.251 -1.305
201906 -0.885 108.070 -1.079
201909 -0.908 108.329 -1.105
201912 -0.540 108.420 -0.656
202003 -0.362 108.902 -0.438
202006 -0.355 108.767 -0.430
202009 -1.155 109.815 -1.386
202012 -0.304 109.897 -0.365
202103 -0.252 111.754 -0.297
202106 -0.241 114.631 -0.277
202109 -0.340 115.734 -0.387
202112 -0.354 117.630 -0.397
202203 -0.200 121.301 -0.217
202206 -0.350 125.017 -0.369
202209 -0.384 125.227 -0.404
202212 -0.349 125.222 -0.367
202303 -0.794 127.348 -0.822
202306 -0.425 128.729 -0.435
202309 -0.431 129.860 -0.437
202312 -0.367 129.419 -0.374
202403 -0.267 131.776 -0.267

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Organovo Holdings  (STU:4OR1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Organovo Holdings Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings (STU:4OR1) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Organovo Holdings (STU:4OR1) Headlines

No Headlines